Astellas Pharma Inc. and the Blood and Marrow Transplant Clinical Trials Network announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation for patients with FMS-like tyrosine kinase 3 -internal tandem duplication mutated acute myeloid leukemia.
